Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M M Oken

Showing results (81-90 of 148) with videos related to

Pageof 15
Sort By:
Cancer|April 1, 1984
High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myelomaR E Lenhard, M M Oken, J M Barnes, et al.
Medical and Pediatric Oncology|January 1, 1978
Comparison of two radioimmunoassays and a microbiologic assay for bleomycinM K Elson, M M Oken, R B Shafer, et al.
Leukemia|June 9, 2012
Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III studyD H Vesole, M M Oken, C Heckler, et al.
British Journal of Haematology|March 21, 1998
T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93N E Kay, T Leong, N Bone, et al.
American Journal of Clinical Oncology|December 1, 1982
Toxicity and response criteria of the Eastern Cooperative Oncology GroupM M Oken, R H Creech, D C Tormey, et al.
Leukemia & Lymphoma|May 1, 1994
An aggressive high dose cyclophosphamide and prednisone regimen for advanced multiple myelomaR E Lenhard, M J Daniels, M M Oken, et al.
Investigational New Drugs|April 9, 2001
Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology GroupB J Giantonio, H Hochster, R Blum, et al.
Seminars in Oncology|June 1, 1987
Prolonged survival after high-dose cytosine arabinoside and amsacrine induction in patients with previously untreated de novo acute nonlymphocytic leukemiaJ D Hines, J J Mazza, M M Oken, et al.
Leukemia|July 18, 2001
Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alpha2a) plus an anthracycline-based induction regimenR V Smalley, E Weller, M J Hawkins, et al.
British Journal of Haematology|February 1, 1988
Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemiaJ J Yunis, M Lobell, M A Arnesen, et al.
Pageof 15

Showing results (81-90 of 148) with videos related to

Sort By:
Pageof 15
Cancer|April 1, 1984
High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myelomaR E Lenhard, M M Oken, J M Barnes, et al.
Medical and Pediatric Oncology|January 1, 1978
Comparison of two radioimmunoassays and a microbiologic assay for bleomycinM K Elson, M M Oken, R B Shafer, et al.
Leukemia|June 9, 2012
Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III studyD H Vesole, M M Oken, C Heckler, et al.
British Journal of Haematology|March 21, 1998
T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93N E Kay, T Leong, N Bone, et al.
American Journal of Clinical Oncology|December 1, 1982
Toxicity and response criteria of the Eastern Cooperative Oncology GroupM M Oken, R H Creech, D C Tormey, et al.
Leukemia & Lymphoma|May 1, 1994
An aggressive high dose cyclophosphamide and prednisone regimen for advanced multiple myelomaR E Lenhard, M J Daniels, M M Oken, et al.
Investigational New Drugs|April 9, 2001
Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology GroupB J Giantonio, H Hochster, R Blum, et al.
Seminars in Oncology|June 1, 1987
Prolonged survival after high-dose cytosine arabinoside and amsacrine induction in patients with previously untreated de novo acute nonlymphocytic leukemiaJ D Hines, J J Mazza, M M Oken, et al.
Leukemia|July 18, 2001
Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alpha2a) plus an anthracycline-based induction regimenR V Smalley, E Weller, M J Hawkins, et al.
British Journal of Haematology|February 1, 1988
Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemiaJ J Yunis, M Lobell, M A Arnesen, et al.
Pageof 15